Precigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete Responses Beyond 4 Years

Source · https://www.prnewswire.com/news-releases/precigen-presents-new-long-term-durability-data-for-papzimeos-recently-granted-seven-year-market-exclusivity-demonstrating-complete-responses-beyond-4-years-302786302.html

Read source

Precigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete Responses Beyond 4 Years

Search tags

What matters in this story

PAPZIMEOS has been granted seven-year market exclusivity by the FDA as the first and only approved therapy for adult recurrent respiratory papillomatosis (RRP). — A seven-year monopoly in an untapped market for a specific disease provides a high-margin revenue stream with no direct competitors.

+0.80

Updated long-term data shows 83% of complete responders maintained their response after 36 months, with some remaining surgery-free beyond 4 years. — Demonstrated long-term durability is critical for adoption and pricing power in rare disease therapies, shifting the standard of care away from surgery.

+0.60

Precigen estimates there are approximately 27,000 adult RRP patients in the United States. — Provides a concrete Total Addressable Market (TAM) for analysts to project potential peak sales for the drug.

+0.40

Precigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete Responses Beyond 4 Years

What matters in this story

Kelun-Biotech Presents Pivotal Phase II Data for Lunbotinib Fumarate (A400/EP0031) in RET Fusion-Positive NSCLC at 2026 ASCO

Precigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete Responses Beyond 4 Years

What matters in this story

Kelun-Biotech Presents Pivotal Phase II Data for Lunbotinib Fumarate (A400/EP0031) in RET Fusion-Positive NSCLC at 2026 ASCO

Sentiment in this article

Relationships in this article

Analytical profile by cluster

Top impact dimensions

Most positively impacted

Most negatively impacted

Eikon Therapeutics Presents Data on Clinical-Stage Programs at the 2026 Annual Meeting of the American Society of Clinical Oncology

Whitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026

Global Data for BioNTech and Bristol Myers Squibb's PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial

ImmunityBio: Anktiva Explained and What Comes Next

Menarini Group presenta nuevos datos del estudio ELEVATE de elacestrant en combinación con capivasertib

Precigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete Responses Beyond 4 Years

What matters in this story

Next reads from the same story arc

Kelun-Biotech Presents Pivotal Phase II Data for Lunbotinib Fumarate (A400/EP0031) in RET Fusion-Positive NSCLC at 2026 ASCO

Precigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete Responses Beyond 4 Years

What matters in this story

Next reads from the same story arc

Kelun-Biotech Presents Pivotal Phase II Data for Lunbotinib Fumarate (A400/EP0031) in RET Fusion-Positive NSCLC at 2026 ASCO

Sentiment in this article

Relationships in this article

Analytical profile by cluster

Top impact dimensions

Most positively impacted

Most negatively impacted

Eikon Therapeutics Presents Data on Clinical-Stage Programs at the 2026 Annual Meeting of the American Society of Clinical Oncology

Whitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026

Global Data for BioNTech and Bristol Myers Squibb's PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial

ImmunityBio: Anktiva Explained and What Comes Next

Menarini Group presenta nuevos datos del estudio ELEVATE de elacestrant en combinación con capivasertib